EUCTR2015-002866-21-FR进行中（未招募）1 期
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC RO5534262 VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 109
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Aged 12 years or older at the time of informed consent
- •- Body weight >=40 kg at the time of screening
- •- Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (i.e., >= 5 Bethesda Units)
- •- Documentation of treatment with episodic or prophylactic bypassing agents for at least the last 24 weeks
- •- Adequate hematologic function
- •- Adequate hepatic function
- •- Adequate renal function
- •- For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined highly effective non-hormonal contraceptive methods
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 63
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •- Inherited or acquired bleeding disorder other than hemophilia A
- •- Ongoing (or plan to receive during the study) immune tolerance induction therapy or prophylaxis with FVIII
- •- History of illicit drug or alcohol abuse within 48 weeks prior to screening, in the investigator’s judgment
- •- Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which antithrombotic treatment is not currently ongoing) or signs of thromboembolic disease
- •- Previous or concurrent autoimmune or connective tissue disease
- •- History of hypersensitivity associated with monoclonal antibody therapies or components of the RO5534262 injection
- •- Known HIV infection with CD4 count < 200 cells/microliter within 24 weeks prior to screening
- •- Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use during the study, with the exception of antiretroviral therapy
- •- Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient’s safe participation in and completion of the study or interpretation of the study results
- •- Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
- •- Receipt of
- •RO5534262 in a prior investigational study
- •An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration
- •A non-hemophilia-related investigational drug within last 30 days or 5 half lives, whichever is shorter
- •An investigational drug concurrently
- •- Unwillingness to use highly effective contraception methods for the specified duration in the protocol (females only, unless required otherwise by the local health authority)
- •- Clinically significant abnormality on screening evaluations or laboratory tests that, in the opinion of the investigator, may pose an additional risk in administering study drug to the patient
- •- Pregnancy or lactation, or intent to become pregnant during the study
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Prophylactic Emicizumab Versus no Prophylaxis in Haemophilia A Patients Without InhibitorsHaemophilia A without factor VIII inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053753Term: Hemophilia A without inhibitorsSystem Organ Class: 100000004850EUCTR2016-000072-17-GBF. Hoffmann-La Roche Ltd152
已完成
3 期
Phase III clinical trial of emicizumab in hemophilia A patients with inhibitorsHemophilia A with inhibitorsJPRN-jRCT2080222987Chugai Pharmaceutical Co., Ltd.109
进行中（未招募）
不适用
A Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.HER2-positive operable primary breast cancer.MedDRA version: 14.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004902-82-ESF. Hoffmann-La Roche Ltd2,500
进行中（未招募）
1 期
A Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.EUCTR2012-004902-82-PLF. Hoffmann-La Roche Ltd1,846
进行中（未招募）
1 期
A Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.HER2-positive operable primary breast cancer.MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004902-82-BEF. Hoffmann-La Roche Ltd1,846